Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 401–500 of 1,025
Yusuf, T. E., Matthes, K., & Brugge, W. R. (2008) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2007.08.020 · Cited by 97
Ophthalmic Antibiotics and Antimicrobial Resistance
Kim, S. J., & Toma, H. S. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.014 · Cited by 99
“1 i e i C t I o l l m A Age-related macular degeneration (AMD) is the leading cause of blindness among individuals older than 65 years in the United States and currently affects more than 8 million Americans.1 The overall prevalence of advanced AMD is projected to increase by more than 50% by the year 2020.2 Monthly i…”
BackgroundInfluentialSuzuki, M., Nagai, N., Izumi‐Nagai, K., Shinoda, H., Koto, T., Uchida, A., Mochimaru, H., Yuki, K., Sasaki, M., Tsubota, K., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304670 · Cited by 103
Jaffe, G. J., Eliott, D., Wells, J. A., Prenner, J. L., Papp, A., & Patel, S. C. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.004 · Cited by 97
Subramanian, M. L., Abedi, G., Ness, S. D., Ahmed, E., Fenberg, M. J., Daly, M. K., Houranieh, A. M., & Feinberg, E. B. (2010) · Eye · doi:10.1038/eye.2010.147 · Cited by 105
Schmid, M., Bachmann, L. M., Faes, L., Kessels, A. G. H., Job, O. M., & Thiel, M. A. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305149 · Cited by 96
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
Khachigian, L. M., Liew, G., Teo, K. Y. C., Wong, T. Y., & Mitchell, P. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03937-7 · Cited by 104
“The MARINA [78] and ANCHOR [79] trials showed gains of about 2 lines over 24 months.”
BackgroundMethodElSheikh, R. H., Chauhan, M. Z., & Sallam, A. B. (2022) · Biomolecules · doi:10.3390/biom12111629 · Cited by 98
“The multicentric randomized ANCHOR trial evaluated the efficacy of intravitreal ranibizumab in patients with predominantly classic CNVs [40].”
BackgroundInfluentialFalk, M. K., Kemp, H., & Sørensen, T. L. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.06.031 · Cited by 97
“6% of patients were able to identify a minimum of 70 letters at 12 months from baseline.(15) In theMARINA study, these figures were 15% and 40%, respectively, and at months 24, there was a further increase to 42%.”
BackgroundCorey, D. R. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0107-8 · Cited by 97
INFECTIOUS ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTIANGIOGENIC AGENTS
Diago, T., McCannel, C. A., Bakri, S. J., Pulido, J. S., Edwards, A. O., & Pach, J. M. (2009) · Retina · doi:10.1097/iae.0b013e31819d2591 · Cited by 97
Guidance for the treatment of neovascular age-related macular degeneration
Schmidt-Erfurth, U. M., Richard, G. W., Augustin, A. J., Aylward, G. W., Bandello, F. M., Corcóstegui, B., Cunha-Vaz, J. G., Gaudric, A., LEYS, A. M., & Schlingemann, R. O. (2007) · Acta Ophthalmologica Scandinavica · doi:10.1111/j.1600-0420.2007.00979.x · Cited by 96
“The Anti-VEGF antibody for the treatment of predominantly classic choroidal neovascularization in agerelated macular degeneration (ANCHOR) study comprised 423 patients with predominantly classic subfoveal CNV because of AMD in a prospective, randomized phase III trial design (Brown et al. 2006).”
BackgroundInfluentialCampa, C., Costagliola, C., Incorvaia, C., Sheridan, C., Semeraro, F., Nadai, K. D., Sebastiani, A., & Parmeggiani, F. (2010) · Mediators of Inflammation · doi:10.1155/2010/546826 · Cited by 102
“Mean VA demonstrated an improvement of 11 letters in one year and a final VA of 20/40 or better was found in 39% of ranibizumabtreated patients [114].”
BackgroundBae, S. H., Heo, J. W., Kim, C., Kim, T. W., Lee, J. Y., Song, S. J., Park, T. K., Moon, S. W., & Chung, H. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.04.008 · Cited by 96
Recent Advances in Age-Related Macular Degeneration Therapies
Fabre, M., Mateo, L., Lamaa, D., Baillif, S., Pagès, G., Demange, L., Ronco, C., & Benhida, R. (2022) · Molecules · doi:10.3390/molecules27165089 · Cited by 110
Choroidal Neovascularization in Pathologic Myopia: Recent Developments in Diagnosis and Treatment
Soubrane, G. (2008) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2007.12.004 · Cited by 95
Self-citationCiulla, T. A., & Rosenfeld, P. J. (2009) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328329d173 · Cited by 96
Pellé, G., Shweke, N., Huyen, J. D. V., Tricot, L., Hessaïne, S., Frémeaux‐Bacchi, V., HIESSE, C., & Delahousse, M. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.11.030 · Cited by 95
Cunningham, E. T., Feiner, L., Chung, C. Y., Tuomi, L., & Ehrlich, J. S. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.05.026 · Cited by 94
Luo, L., Zhang, X., Hirano, Y., Tyagi, P., Barabás, P., Uehara, H., Miya, T. R., Singh, N., Archer, B. J., Qazi, Y., et al. (2013) · ACS Nano · doi:10.1021/nn305958y · Cited by 98
“visual acuity with intravitreal anti-VEGF injection therapy.(10,12,29)”
Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases
Sharma, D., Zachary, I. C., & Jia, H. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.5.28 · Cited by 105
Patel, K. H., Chow, C. C., Rathod, R., Mieler, W. F., Lim, J. I., Ulanski, L., Leiderman, Y. I., Arun, V., & Chau, F. Y. (2013) · Eye · doi:10.1038/eye.2013.31 · Cited by 95
Current Anti–Vascular Endothelial Growth Factor Dosing Regimens
Haller, J. A. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.057 · Cited by 94
“5 mg ranibizumab or a sham injection, whereas those in ANCHOR were randomized to monthly injections of either dosage or to verteporfin photodynamic therapy.(3,4) In MARINA, patients receiving the 0.”
Bell, C. M., Gill, S. S., Bronskill, S. E., Paterson, J. M., Whitehead, M., & Bell, C. M. (2012) · BMJ · doi:10.1136/bmj.e4203 · Cited by 105
Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
Tan, C. S., Ngo, W. K., Chay, I. W., Ting, D. S., & Sadda, S. R. (2022) · Clinical ophthalmology · doi:10.2147/opth.s231913 · Cited by 100
“6% of the verteporfin group.(8) While these two studies showed that ranibizumab prevented visual loss and disease progression in the short term, these agents do not assure long-term visual stability or disease quiescence.”
BackgroundShienbaum, G., Filho, C. A. D. A. G., Flynn, H. W., Nunes, R. P., Smiddy, W. E., & Rosenfeld, P. J. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.01.012 · Cited by 94
Algvere, P. V., Steén, B., Seregard, S., & Kvanta, A. (2008) · Acta Ophthalmologica · doi:10.1111/j.1600-0420.2007.01113.x · Cited by 92
“2008: 86: 482–489 ª 2007 The Authors Journal compilation ª 2007 Acta Ophthalmol Scand doi: 10.1111/j.1600-0420.2007.01113.x AMD (Brown et al. 2006; Rosenfeld 2006; Boyer et al. 2007).”
InfluentialPegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
Takeda, A. L., Colquitt, J., Clegg, A. J., & Jones, J. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.118562 · Cited by 91
Croft, D. E., Hemert, J. I. V., Wykoff, C. C., Clifton, D. A., Verhoek, M., Fleming, A. D., & Brown, D. M. (2014) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20140709-07 · Cited by 92
Self-citationTherapeutic Anti-VEGF Antibodies
Lien, S., & Lowman, H. B. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_6 · Cited by 101
“When compared with verteporfin at 12 months (Brown et al. 2006), ranibizumab treatment led to 94.”
MethodEfficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
Kunimoto, D., Yoon, Y. H., Wykoff, C. C., Chang, A., Khurana, R. N., Maturi, R. K., Agostini, H., Souied, E., Chow, D. R., Lotery, A. J., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.035 · Cited by 91
Lee, S. J., & Koh, H. J. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.04.015 · Cited by 96
Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration
Fong, D. S., Custis, P. H., Howes, J., & Hsu, J. Y. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.07.023 · Cited by 92
Review of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy
Jardeleza, M. S. R., & Miller, J. W. (2009) · Seminars in Ophthalmology · doi:10.1080/08820530902800330 · Cited by 93
Narita, C., Wu, Z., Rosenfeld, P. J., Yang, J. Y., Lyu, C., Caruso, E., McGuinness, M. B., & Guymer, R. H. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.11.007 · Cited by 95
Hadziahmetovic, M., & Malek, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.612812 · Cited by 90
Structure-Function Correlation of the Human Central Retina
Issa, P. C., Troeger, E., Finger, R. P., Holz, F. G., Wilke, R. G. H., & Scholl, H. P. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012864 · Cited by 92
“Investigating treatment effectiveness by high-resolution imaging has very recently gained tremendous importance because retinal pharmacotherapy, especially vascular endothelial growth factor A (VEGF-A) inhibition, has revolutionized therapy of macular diseases [4,5,6,7,8].”
BackgroundCruess, A. F., Zlateva, G., Pleil, A. M., & Wirostko, B. M. (2008) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2008.01218.x · Cited by 96
“…prospective (Japanese Age-related Macular Degeneration Trial [JAT] Study Group 2003; Sharma et al. 2004; Arias et al. 2005; Michels et al. 2005; Brown et al. 2006; Heier et al. 2006; Slakter et al. 2006; Gelisken et al. 2007) and retrospective (Essex et al. 2003; Axer-Siegel et al. 2004a;…”
BackgroundDiabetic retinopathy – An update
Alghadyan, A. A. (2011) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2011.01.009 · Cited by 107
Brown, D. M., Chen, E., Mariani, A., & Major, J. C. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.008 · Cited by 90
Self-citationde Ávila, M. P., Farah, M. E., Santos, A., Duprat, J. P., Woodward, B. W., & Nau, J. A. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.145912 · Cited by 90
Comparing protein VEGF inhibitors: In vitro biological studies
Yu, L., Liang, X. H., & Ferrara, N. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.014 · Cited by 93
Rosenberg, D., Deonarain, D. M., Gould, J., Sothivannan, A., Phillips, M., Sarohia, G. S., Sivaprasad, S., Wykoff, C. C., Cheung, C. M. G., Sarraf, D., et al. (2022) · Eye · doi:10.1038/s41433-022-02020-7 · Cited by 97
Framme, C., Wolf, S., & Wolf-Schnurrbusch, U. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5779 · Cited by 89
Sayanagi, K., Sharma, S. K., Yamamoto, T., & Kaiser, P. K. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.11.002 · Cited by 90
Self-citationYamashiro, K., Tomita, K., Tsujikawa, A., Nakata, I., Akagi-Kurashige, Y., Miyake, M., Ooto, S., Tamura, H., & Yoshimura, N. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.01.010 · Cited by 93
Lai, T. Y. Y., Chan, W., LIU, D. T. L., & Lam, D. S. C. (2009) · Retina · doi:10.1097/iae.0b013e31819ed6bd · Cited by 89
Hussain, R. M., & Ciulla, T. A. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1362390 · Cited by 88
“the landmark MARINA and ANCHOR trials, respectively [4,13].”
BackgroundResultInfluentialMatsumoto, H., Hiroe, T., Morimoto, M., Mimura, K., Ito, A., & Akiyama, H. (2018) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-018-0562-0 · Cited by 93
Spitzer, M. S., Yoeruek, E., Sierra, A., Wallenfels-Thilo, B., Schraermeyer, U., Spitzer, B., Bartz‐Schmidt, K. U., & Szurman, P. (2007) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0568-7 · Cited by 92
“In contrast, in clinical trials where patients received pegaptanib for neovascular AMD only stabilisation of visual acuity could be achieved in the majority of patients [7].”
BackgroundInfluentialChan, W., Lai, T. Y. Y., Chan, K. M., Li, H., LIU, D. T. L., Lam, D. S. C., & Pang, C. (2008) · Retina · doi:10.1097/iae.0b013e31818358b2 · Cited by 89
Low-Fluence Photodynamic Therapy versus Ranibizumab for Chronic Central Serous Chorioretinopathy
Bae, S. H., Heo, J., Kim, C., Kim, T. W., Shin, J. Y., Lee, J. Y., Song, S. J., Park, T. K., Moon, S. W., & Chung, H. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.024 · Cited by 89
Intersession Repeatability of Visual Acuity Scores in Age-Related Macular Degeneration
Patel, P. J., Chen, F. K., Rubin, G. S., & Tufail, A. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-1935 · Cited by 91
Bhisitkul, R. B., Desai, S. J., Boyer, D. S., Sadda, S. R., & Zhang, K. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.033 · Cited by 93
Rosenfeld, P. J. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19969 · Cited by 95
“35 As mentioned previously, OCT imaging was useful in demonstrating the anatomic improvements that followed ranibizumab therapy, and selected sites performed OCT imaging during the phase III ranibizumab trials for neovascular AMD known as the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the…”
MethodHolekamp, N. M., Liu, Y., Yeh, W.-S., Chia, Y., Kiss, S., Almony, A., & Kowalski, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.12.018 · Cited by 88
da Silva, R. M., Axer‐Siegel, R., Eldem, B., Guymer, R. H., Kirchhof, B., Papp, A., Seres, A., Gekkieva, M., Nieweg, A., & Pilz, S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.026 · Cited by 89
Bressler, N. M., Boyer, D. S., Williams, D. F., Butler, S., Francom, S. F., Brown, B., Nucci, F. D., Cramm, T., Tuomi, L. L., Ianchulev, T., et al. (2012) · Retina · doi:10.1097/iae.0b013e31825db6ba · Cited by 88
Smartphones, tele-ophthalmology, and VISION 2020
Mohammadpour, M., Heidari, Z., Mirghorbani, M., & Hashemi, H. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.12.19 · Cited by 88
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Kaiser, S., Arepalli, S., & Ehlers, J. P. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259298 · Cited by 90
Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
Folk, J. C., & Stone, E. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmct1000495 · Cited by 91
Liakopoulos, S., Ongchin, S. C., Bansal, A. S., Msutta, S., Walsh, A. C., Updike, P. G., & Sadda, S. R. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-1877 · Cited by 89
London, N. J. S., Garg, S. J., Moorthy, R. S., & Cunningham, E. T. (2013) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/1869-5760-3-43 · Cited by 97
“These agents are used for the treatment of a number of retinal disorders, including exudative age-related macular degeneration (AMD), diabetic macular edema, neovascular glaucoma, and macular edema associated with retinal vein occlusion (RVO) [127-143].”
Lang, G., Jiang, Y., Shi, J., Yang, F., Li, X., Pei, Y., Zhang, C., Ma, D., Xiao, Y., Hu, P.-C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19342-3 · Cited by 93
Hussain, R. M., Shaukat, B. A., Ciulla, L. M., Berrocal, A. M., & Sridhar, J. S. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s295223 · Cited by 93
“Landmark trials such as the ANCHOR study demonstrated superiority of anti-VEGF injections over photodynamic therapy for preserving and recovering visual acuity.(74) The currently available anti-VEGF-A medications in North America include bevacizumab, ranibizumab, aflibercept and brolucizumab.”
BackgroundLois, N., Mcbain, V., Abdelkader, E., Scott, N. W., & Kumari, R. (2013) · Retina · doi:10.1097/iae.0b013e3182657fff · Cited by 88
“After monthly regimens, excellent visual outcomes can be obtained, with more than 90% of patients expected to maintain their vision and 30% to 40% to experience visual improvement.(1,2) Alternative strategies to monthly injections are widely used in clinical practice, despite the fact that visual outcomes are not as f…”
BackgroundPrevalence of Ocular Fundus Pathology in Patients with Chronic Kidney Disease
Grunwald, J. E., Alexander, J., Maguire, M. G., Whittock, R., Parker, C., McWilliams, K., Lo, J. C.-M., Townsend, R. R., Gadegbeku, C. A., Lash, J. P., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08271109 · Cited by 87
Wang, Y., He, Y.-G., Mitzel, G. M., Zhang, S., & Bartlett, M. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12037 · Cited by 90
“By comparison, previous studies using various dSDH testing protocols have shown the following characteristics of the SDH test: (1) it is a hyperacuity test and is spatial frequency band limited(28) around the peak CS (3 cyc/deg in the hSDH test) so that it is much less affected by the deterioration of the eye’s optica…”
BackgroundMethodResultInfluentialXie, B., Shen, J., Dong, A., Rashid, A., STOLLER, G. L., & Campochiaro, P. A. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21588 · Cited by 89
“Intraocular injections of ranibizumab, a Fab that binds all isoforms of VEGF-A, causes substantial visual improvement in 34–40% of patients with choroidal NV due to AMD (Brown et al., 2006; Rosenfeld et al., 2006).”
BackgroundInfluentialArcinue, C. A., Ma, F., Barteselli, G., Sharpsten, L., Gomez, M. L., & Freeman, W. R. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.11.022 · Cited by 95
Wang, X., Sawada, T., Sawada, O., Saishin, Y., Liu, P., & Ohji, M. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.06.009 · Cited by 86
Pharmacotherapy for uveitis: current management and emerging therapy
Denniston, A. K., Barry, R. J., Nguyen, Q. D., Lee, R., & Murray, P. I. (2014) · Clinical ophthalmology · doi:10.2147/opth.s47778 · Cited by 96
“Whilst systemic side effects are rare, the risk of serious cardiovascular events remains a topic of debate.(189,190)”
Wykoff, C. C., Brown, D. M., Maldonado, M. E., & Croft, D. E. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304736 · Cited by 96
Self-citationSustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles
Tsujinaka, H., Fu, J., Shen, J., Yu, Y., Hafiz, Z., Kays, J. C., McKenzie, D. A., Cardona, D., Culp, D., Peterson, W. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14340-x · Cited by 89
Vedula, S. S., & Krzystolik, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub2 · Cited by 87
Fauser, S., Schwabecker, V., & Muether, P. S. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.05.025 · Cited by 85
Stein, J. D., Newman-Casey, P. A., Mrinalini, T., Lee, P. P., & Hutton, D. W. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.037 · Cited by 84
“The Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trial showed that either dose was better than PDT with verteporfin.(12)More recently, two large randomized controlled trials, the Comparison of Age-Related Macular Degeneration Treatment Trial (CATT)(13,14) a…”
Modelling the Genetic Risk in Age-Related Macular Degeneration
Grassmann, F., Fritsche, L. G., Keilhauer, C. N., Heid, I. M., & Weber, B. H. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037979 · Cited by 85
“To date, effective therapeutic intervention is available for active NV, while GA still remains untreatable [4,5].”
BackgroundKertes, P. J., Galic, I. J., Greve, M. D. J., Williams, G., Rampakakis, E., Scarino, A., & Sheidow, T. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.01.013 · Cited by 86
Lipécz, Á., Miller, L. R., Kovács, I., Czakó, C. N., Csípő, T., Baffi, J., Csiszár, A., Tarantini, S., Ungvari, Z. I., Yabluchanskiy, A., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00138-3 · Cited by 93
BARBAZETTO, I. A., Saroj, N., Shapiro, H., Wong, P., Ho, A. C., & Freund, K. B. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.01.007 · Cited by 89
Management of retinal vascular diseases: a patient-centric approach
Brand, C. (2012) · Eye · doi:10.1038/eye.2012.32 · Cited by 88
Meredith, T. A., McCannel, C. A., Barr, C., Doft, B. H., Peskin, E., Maguire, M. G., Martin, D. F., & Prenner, J. L. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.10.027 · Cited by 84
Sponer, U., Waldstein, S. M., Kundi, M., Ritter, M., Golbaz, I., Heiling, U., Papp, A., Simader, C., & Schmidt-Erfurth, U. M. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.05.032 · Cited by 86
Bracha, P., Moore, N. A., Ciulla, T. A., WuDunn, D., & Cantor, L. B. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.08.008 · Cited by 86
Potential Therapeutic Effects of Baicalein, Baicalin, and Wogonin in Ocular Disorders
Xiao, J.-R., Wai, C., & To, C. H. (2014) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0074 · Cited by 89
Hatz, K. B., & Prünte, C. F. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303444 · Cited by 87
Fine, H. F., ZHITOMIRSKY, I., Freund, K. B., Barile, G. R., Shirkey, B. L., Samson, C. M., & Yannuzzi, L. A. (2009) · Retina · doi:10.1097/iae.0b013e318187aff9 · Cited by 84
Hsu, J., Gerstenblith, A. T., Garg, S. J., & VANDER, J. F. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.10.003 · Cited by 84
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Agrawal, S., Joshi, M., & Christoforidis, J. B. (2013) · Mediators of Inflammation · doi:10.1155/2013/943409 · Cited by 83
Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020
Samanta, A., Aziz, A. A., Jhingan, M., Singh, S. R., Khanani, A. M., & Chhablani, J. K. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000291 · Cited by 85
Laser photocoagulation for neovascular age-related macular degeneration
Virgili, G., & Bini, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004763.pub2 · Cited by 99
INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF INFLAMMATORY CHOROIDAL NEOVASCULARIZATION
Rouvas, A., Petrou, P., Douvali, M., Ntouraki, A., Vergados, I. A., Georgalas, I., & Markomichelakis, N. (2011) · Retina · doi:10.1097/iae.0b013e3182003ca8 · Cited by 83
Chakravarthy, U., Bailey, C., Brown, D., Campochiaro, P., Chittum, M., Csaky, K., Tufail, A., Yates, P., Cech, P., Giraudon, M., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.003 · Cited by 82
Self-citationGologorsky, D., Thanos, A., & Vavvas, D. G. (2012) · Mediators of Inflammation · doi:10.1155/2012/629452 · Cited by 90
Lukason, M., DuFresne, E., Rubin, H., Pechan, P., Li, Q., Kim, I., Kiss, S., Flaxel, C., Collins, M., Miller, J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.230 · Cited by 81
Gammons, M. V. R., Fedorov, O., Ivison, D., Du, C., Clark, T., Hopkins, C., Hagiwara, M., Dick, A. D., Cox, R. J., Harper, S. J., et al. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12422 · Cited by 89
“Hua and colleagues determined an effective rhVEGF165b dose in humans of 3 lg/eye, 1000- to 10-fold lower than ranibizumab or bevacizumab.(24) It is difficult to directly compare human-specific ranibizumab to the SRPIN340 efficacy data in mouse, but compared with rhVEGF-A165b, SRPIN340 was 160 times less potent,(20) bu…”
BackgroundChang, L. K. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.7.941 · Cited by 82
“Based on the assumption of a common pathophysiology, intravitreous bevacizumab has been used in the treatment of CNV from etiologies other than AMD, including myopia,10-16 angioid streaks,17,18 central serous chorioretinopathy,19 punctuate inner choroidopathy,19 and idiopathic CNV.20 However, the sample size and follo…”
InfluentialDedania, V. S., & Bakri, S. J. (2015) · Retina · doi:10.1097/iae.0000000000000520 · Cited by 84
Broadhead, G., Grigg, J., McCluskey, P., Hong, T., Schlub, T. E., & Chang, A. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-4163-x · Cited by 87
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.